CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...